NMR structure of the channel-former zervamicin IIB in isotropic solvents

AbstractSpatial structure of the membrane channel-forming hexadecapeptide, zervamicin IIB, was studied by NMR spectroscopy in mixed solvents of different polarity ranging from CDCl3/CD3OH (9:1, v/v) to CD3OH/H2O (1:1, v/v). The results show that in all solvents used the peptide has a very similar structure that is a bent amphiphilic helix with a mean backbone root mean square deviation (rmsd) value of ca. 0.3 Å. Side chains of Trp1, Ile2, Gln3, Ile5 and Thr6 are mobile. The results are discussed in relation to the validity of the obtained structure to serve as a building block of zervamicin IIB ion channels

GENERALIZED ANALYSIS OF MONOCLONAL ANTIBODIES TO IGE IN THE TREATMENT OF BRONCHIAL ASTHMA IN CHILDREN IN RUSSIAN FEDERATION

The article presents a generalized 2-year Russian experience in the application of monoclonal antibodies to IgE in children and adolescents with severe, resistant to standard treatment of bronchial asthma. Data on 65 patients treated with anti-IgE therapy with omalizumab within more than 6 months period in 6 centers of the Russian Federation from 2007 to 2010 were analyzed. The results of this analysis demonstrate the safety and high clinical effectiveness of anti-IgE-therapy in children and adolescents with severe uncontrolled atopic bronchial asthma. Full control of the disease or marked improvement can be achieved in 73% patients, the effect in most cases significantly increases during the first 6 months of treatment and becomes stable in the future, providing a good quality of life and normal lung function.Key words: bronchial asthma, anti-IgE-therapy, treatment, adolescents, children, quality of life, omalizumab

ОБОБЩЕННЫЙ АНАЛИЗ ПРИМЕНЕНИЯ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К IGE В ЛЕЧЕНИИ БРОНХИАЛЬНОЙ АСТМЫ У ДЕТЕЙ В РФ

The article presents a generalized 2-year Russian experience in the application of monoclonal antibodies to IgE in children and adolescents with severe, resistant to standard treatment of bronchial asthma. Data on 65 patients treated with anti-IgE therapy with omalizumab within more than 6 months period in 6 centers of the Russian Federation from 2007 to 2010 were analyzed. The results of this analysis demonstrate the safety and high clinical effectiveness of anti-IgE-therapy in children and adolescents with severe uncontrolled atopic bronchial asthma. Full control of the disease or marked improvement can be achieved in 73% patients, the effect in most cases significantly increases during the first 6 months of treatment and becomes stable in the future, providing a good quality of life and normal lung function.Key words: bronchial asthma, anti-IgE-therapy, treatment, adolescents, children, quality of life, omalizumab.В статье представлен обобщенный 2-летний российский опыт применения моноклональных антител к IgE у детей и подростков с тяжелой, резистентной к стандартному лечению, бронхиальной астмой. Проанализированы данные 65 больных, получавших анти-IgE терапию омализумабом более 6 мес, в 6 центрах РФ с 2007 по 2010 гг. Результаты проведенного анализа свидетельствуют о безопасности и высокой клинической эффективности анти- IgE-терапии у детей и подростков с тяжелой неконтролируемой атопической бронхиальной астмой. Полного контроля болезни или выраженного улучшения удалось достичь у 73% пациентов, эффект в большинстве случаев значимо нарастает в первые 6 мес лечения и является стабильным в дальнейшем, обеспечивая хорошее качество жизни и нормальные показатели функции легких. Ключевые слова: бронхиальная астма, анти-IgE-терапия, лечение, подростки, дети, качество жизни, омализумаб. (Педиатрическая фармакология –2011; 8(2): 50-56